Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB261 in Relapsed or Refractory B-Cell NHL and CLL
NCT04923048Phase 2Unknown
- Sponsor
- Genor Biopharma
- Start
- Aug 2021
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GB261 in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL), sponsored by Genor Biopharma. Primary endpoints: Maximum Tolerated Dose at 21 days, Dose Limiting Toxicity at 21 days and 2 more. Status: unknown.
02
Drugs
GB261
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04923048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04923048.